Spironolactone Doubles Post-Stroke Blood Pressure Control Rate at Three Months: REDUCE Trial

November 9, 2026:

Spironolactone Doubles Post-Stroke Blood Pressure Control Rate at Three Months: REDUCE Trial
Italy's medic NGO Intersos Camilla Faragona checks
Italy’s medic with NGO Intersos, Camilla Faragona, checks a man’s blood pressure in a van parked outside the Borgo Mezzanone makeshift camp hosting migrant workers near Foggia in the Apulia region, in southern Italy, on 23 June 2026. Intersos provides basic healthcare services to migrants living in the camp and operates a mobile clinic that regularly visits the settlement. During the peak summer season, it becomes home to approximately 3,000 peoplemostly migrant farmworkers drawn to Puglia for the tomato harvest and high temperatures are making conditions even worse for migrant workers with a lack of basic services like water current, no sewage system, open air pile of trash.
Tiziana FABI/AFP via Getty Images

For the more than 800,000 Americans who suffer a stroke each year, the most dangerous days are often the ones that follow. Nearly one in four survivors will have another stroke, and uncontrolled high blood pressure is the single most powerful modifiable risk factor driving that recurrence. Yet fewer than 40 percent of patients after a brain bleed manage to get their pressure under control — a clinical gap that researchers have struggled to close for years despite a pharmacopeia full of options.

New results presented Saturday at the American Heart Association’s Scientific Sessions 2026 in Chicago suggest that a decades-old, low-cost diuretic already sitting on pharmacy shelves may offer a meaningful solution. The REDUCE trial — shorthand for Regulating Blood Pressure During Recovery from Intracerebral Hemorrhage and Ischemic Stroke — found that adding daily spironolactone to standard post-stroke care drove average home systolic blood pressure nearly 8 mmHg lower at three months, and roughly doubled the share of patients who reached the guideline-recommended target of less than 130/80 mmHg. Generic spironolactone costs roughly $5 to $18 for a month’s supply.

What the Trial Did

REDUCE is a multicenter, randomized clinical trial evaluating the addition of spironolactone for patients with uncontrolled high blood pressure after either an ischemic stroke (caused by a clot) or an intracerebral hemorrhage — commonly called a brain bleed — caused by a ruptured blood vessel. The primary outcome was home-measured systolic blood pressure at three months, a real-world endpoint that reflects the kind of monitoring patients do between clinic visits rather than a single office reading that can be inflated by the stress of the visit itself.

The trial enrolled 160 adult stroke survivors with an average age of 63. Thirty-eight percent were women, 29 percent self-identified as Black adults, and 16 percent as Hispanic adults. About half of participants had survived a hemorrhagic stroke; the other half an ischemic stroke. The demographic breadth is notable for a trial of this size — minority populations are historically underrepresented in hypertension studies despite bearing a disproportionate burden of stroke.

Participants enrolled between April 2021 and October 2025 at five U.S. academic medical centers: Yale New Haven Hospital, the Hospital of the University of Pennsylvania, Atrium Health Wake Forest Baptist Medical Center, Temple University Hospital, and the University of Texas Health Science Center at Houston, as recorded in the trial’s ClinicalTrials.gov registration. All had uncontrolled high blood pressure, with an average baseline home systolic reading of 136 mmHg.

The study used a pragmatic, randomized, open-label, blinded-endpoint design — an approach known by the acronym PROBE — comparing spironolactone-containing antihypertensive regimens against standard regimens based on 2017 AHA/ACC guidelines. Participants were enrolled at least three weeks after their stroke event, early enough to test whether prompt intervention matters but late enough for the acute phase to have resolved.

The Numbers

The headline findings are hard to dismiss. People taking spironolactone daily had a home-measured systolic blood pressure that was nearly 8 mmHg lower on average than the standard-care group — about 126 mmHg versus 133 mmHg at three months.

Diastolic blood pressure, the bottom number, also improved, dropping by about 4 mmHg on average in the spironolactone group compared with those receiving standard post-stroke care.

The difference in reaching the clinical target was even starker. At three months, 52 percent of people taking the diuretic had reached the blood pressure goal of less than 130/80 mmHg, compared with 30 percent of people in the standard-care group. The benefit was not fleeting: at six months, people in the spironolactone group had systolic blood pressure that was about 7 mmHg lower than controls, suggesting sustained rather than transient efficacy.

The Drug: How It Works and Why It May Be Especially Well-Matched Here

Spironolactone is not a newcomer. First synthesized in the 1950s and approved by the FDA in 1960, it is currently indicated to treat heart failure, high blood pressure, fluid buildup related to liver or kidney disease, and a hormone condition called primary hyperaldosteronism. It is also prescribed off-label for acne and hair loss, and experienced a clinical renaissance in the late 1990s and early 2000s when large trials demonstrated that it substantially cut mortality in heart failure — a finding established by the 1999 RALES trial in NEJM — and reduced deaths and hospitalizations after heart attacks (the EPHESUS trial, 2003).

The drug’s mechanism is specific: it competitively binds the mineralocorticoid receptor (MR) in the distal tubule and collecting duct of the kidney. Aldosterone, a hormone produced by the adrenal glands, normally activates those receptors — triggering the upregulation of epithelial sodium channels and sodium-potassium pumps that cause the kidneys to retain sodium and water while excreting potassium. The result is expanded blood volume and elevated arterial pressure. By blocking aldosterone from reaching its receptor, spironolactone prompts the kidneys to shed more sodium and fluid, reducing blood volume and, with it, the pressure on vessel walls.

That aldosterone-blocking mechanism may be particularly well-matched to the post-stroke population for reasons that reach beyond ordinary hypertension. Preliminary sub-studies from the REDUCE trial itself had flagged that elevated aldosterone levels were strongly associated with persistent high blood pressure in patients who survived a brain bleed — with an odds ratio of 16.52 for failing to control systolic blood pressure in patients with aldosterone at or above 2 nanograms per deciliter, compared with those below that threshold. The implication: overactive aldosterone signaling may be a specific, targetable driver of treatment-resistant blood pressure in this group, not merely the same mechanism that operates in the general hypertensive population.

Separate observational research published in Pharmaceuticals in 2022, which tracked more than 15,000 hypertensive patients in a matched cohort design, found that spironolactone use was associated with a hazard ratio of 0.59 for total stroke risk in the propensity-score-matched cohort — consistent with a protective effect that extends beyond simple blood pressure reduction to include possible vascular stabilization and anti-inflammatory effects on cerebral blood vessels.

Despite this scientific rationale, spironolactone is currently positioned as a fourth-line agent for high blood pressure in U.S. guidelines — something typically added only when pressure remains uncontrolled despite three other drugs. REDUCE now provides the first randomized evidence that moving it earlier in the treatment sequence, specifically into post-stroke care from the outset, may pay dividends.

An Unexpected Timing Signal

One of the most clinically actionable findings emerged from an exploratory analysis the investigators had not originally planned as a primary endpoint. Blood pressure dropped more among people who started spironolactone within three months of their stroke than among those who started it later.

Co-lead author Jordana B. Cohen, M.D., M.S.C.E., FAHA — an associate professor of medicine and epidemiology at the Perelman School of Medicine at the University of Pennsylvania, a kidney and blood pressure specialist, and a member of the writing committee for the 2025 AHA hypertension guidelines — described the finding as a surprise.

“We were surprised to see that blood pressure dropped twice as much as we expected,” Cohen said. “In an exploratory analysis, the blood pressure drop was larger in people who started this medication within three months after a stroke.”

The implication is that there may be a window of heightened responsiveness early after stroke — plausibly linked to acute neurohormonal dysregulation in the period immediately following brain injury, during which the renin-angiotensin-aldosterone system (RAAS) may be specifically overactivated and especially responsive to blockade. Animal studies showing spironolactone can reduce ischemic infarct size and improve cerebrovascular tone in stroke-prone hypertensive rats are consistent with this hypothesis.

That window hypothesis will need prospective confirmation in a larger, powered trial. But it gives clinicians a preliminary biological rationale for earlier rather than later prescribing — and shifts the clinical question from “whether” to “when.”

Cohen added: “We hope these findings encourage healthcare professionals to consider adding spironolactone sooner.”

Safety

For a drug that disrupts electrolyte balance, the safety picture was reassuring. Rates of serious side effects requiring hospitalization were similar between both groups: 15 percent in those taking spironolactone and 16 percent in those taking standard post-stroke medications.

Hyperkalemia — elevated potassium — was present in about 4 percent of people in the spironolactone group, but it caused no life-threatening events. Because the drug’s mechanism prevents the kidneys from excreting potassium, rising potassium is the main adverse effect clinicians watch for with mineralocorticoid receptor antagonists, and routine potassium monitoring is standard practice when prescribing spironolactone — particularly in older patients and those with any degree of kidney impairment. The drug is generally contraindicated when kidney filtration function (eGFR) falls below 45.

Gynecomastia — breast tissue enlargement in men — is another known side effect of spironolactone’s hormonal activity that can limit use, though it was not reported as a primary concern in this population.

Limitations and What Comes Next

The investigators were candid about the trial’s constraints. Enrollment ended early at 160 of the planned 200 participants — meaning the study was underpowered relative to its original design — and about 15 percent of participants did not have three-month blood pressure readings available for analysis. Those gaps add statistical uncertainty to the estimates.

The study was not designed or powered to determine whether spironolactone actually lowers the risk of another stroke or heart attack, and larger, longer studies are needed before that question can be answered. The comparison was against usual care rather than against adding a different blood pressure drug at the same stage — leaving open the possibility that any additional antihypertensive, not specifically spironolactone, might produce a similar effect. People in the spironolactone group were also taking slightly more blood pressure medications overall at three months — 2.6 on average versus 2.1 in the control group — which could account for some portion of the BP difference.

The open-label design, in which both participants and clinicians knew the treatment assignment, introduces the possibility of behavior-related confounding, though the use of objective home blood pressure devices provides a measure of protection against reporting bias.

Critically, the results were presented as a late-breaking abstract at AHA Scientific Sessions 2026; full peer review and journal publication have not yet occurred, and the findings remain preliminary pending that process.

Taken together, REDUCE should be read as a strong proof-of-concept with a compelling safety profile — not a practice-changing mandate until a larger, powered trial can confirm the effect on recurrent stroke and cardiovascular events.

Why It Matters: A Clinical Gap and a Policy Moment

Cohen framed the clinical stakes in direct terms. “Strokes can be devastating and are a leading cause of disability,” she said. “Our top goal is to keep patients from having another stroke. Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke.”

The scale of that preventable burden makes even modest improvements in blood pressure control clinically meaningful. Up to 80 percent of strokes are preventable, according to the AHA, and hypertension is the dominant modifiable factor. A reduction of 7 to 8 mmHg in systolic pressure is roughly consistent with the magnitude of benefit associated with adding an entirely new antihypertensive drug class — and spironolactone carries a fraction of the cost of newer agents.

The REDUCE findings also land at a moment when the clinical establishment is beginning to pay more systematic attention to the aldosterone axis. A 2025 Endocrine Society clinical practice guideline now recommends measuring serum aldosterone and the aldosterone-renin ratio in all patients with newly diagnosed hypertension — a sweeping expansion of aldosterone testing aimed at identifying the estimated 1 in 5 treatment-resistant patients who have primary aldosteronism, a condition currently diagnosed in fewer than 3 percent of those affected. Cohen has been among the clinicians advocating for broader aldosterone screening; if that screening becomes standard practice, it could help identify the subset of stroke patients whose treatment-resistant hypertension is specifically driven by aldosterone excess — and who would most benefit from spironolactone.

Cohen, who has led AHA scientific statements on the accuracy standards for cuffless blood pressure monitoring devices and serves on the 2025 AHA hypertension guideline writing committee, has also cautioned — in an October 2026 Healio interview — that AI clinical decision tools “should be shown to be effective, safe, and appropriate before use” before being deployed in blood pressure management workflows — a view consistent with the methodological rigor her own trial reflects in its choice of validated home monitoring devices over algorithmic shortcuts.

The REDUCE findings also reinforce home blood pressure monitoring as a primary endpoint in clinical trials. Home readings capture the ambient pressure patients actually live with, as opposed to clinic readings that can be biased by what cardiologists call the “white coat” effect — a temporary spike caused by the stress of a medical appointment. That methodological choice gives the results direct real-world relevance.

The Bottom Line

REDUCE is a small trial that stopped short of its enrollment target, but it asked an important question with a rigorous design and produced a clinically meaningful signal. For a drug that costs pennies per pill, has a 60-year safety record in millions of patients, and is already FDA-approved for the hypertension indication being studied, the case for a larger definitive trial is now considerably stronger. The next step — a multicenter randomized trial powered specifically for recurrent stroke and cardiovascular events — could reshape how neurologists, nephrologists, and internists approach blood pressure management in the vulnerable months after a brain event. For the 7 million Americans living with the aftermath of a previous stroke, that trial cannot come soon enough.

The REDUCE trial (NCT04760717) was funded by a Bugher Center grant from the American Heart Association and was led by Yale University in collaboration with four additional U.S. academic medical centers. Results were presented as a late-breaking abstract at AHA Scientific Sessions 2026 on November 7, 2026.

Source link